TFF3 and metabolic dysfunction-associated steatotic liver disease: Conversely, intraperitoneal injection of recombinant TFF3 protein or tail-vein injection of adenovirus-mediated TFF3 overexpression ameliorated several indicators associated with NAFLD in diabetic (db/db), obese (ob/ob), and diet-induced obese mice or rats, possibly by mediating hepatic fatty-acid oxidation via increasing peroxisome proliferator-activated receptor-α levels [19] (Fig. 1A).